A 90-day trial involving patients with Type I and Type II diabetes showed that Senseonics‘ (NYSE:SENS) implantable continuous glucose monitor was safe and accurate compared to reference glucose values, according to a study published in Diabetes Technology & Therapeutics.
The single-arm study enrolled 90 participants and implanted them with Senseonics’ Eversense device, which sends glucose data every five minutes to a transmitter. The transmitter then communicates that data to a mobile app, which displays the values in real-time. The system also includes alarms to warn the user if they’re approaching hyper- or hypoglycemia.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.